NDMA reanalysis of pyrilamine data for menstrual cramp claim urged by FDA.
This article was originally published in The Tan Sheet
Executive Summary
NDMA REANALYSIS OF PYRILAMINE DATA MAY SUPPORT MENSTRUAL CRAMP CLAIM, FDA told the Nonprescription Drug Manufacturers Association in a Jan. 3 letter. Referring to two studies submitted by NDMA to support the use of pyrilamine maleate for the relief of premenstrual/menstrual pain and cramps ("The Tan Sheet" May 2, 1994, p. 8), the agency said the data "do not support an indication" for the relief of both premenstrual pain and cramps. However, the agency added, "if the studies are reanalyzed,...they may support a claim for relief of menstrual cramps."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning